Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P910023/S479

Avant DR CDDRA700Q, CDDRA700T; Gallant DR CDDRA500Q, CDDRA500T; Entrant DR CDDRA300Q, CDDRA300T; Neutrino NxT DR CDD

ABBOTT MEDICAL · Decision date Aug 27, 2025

FDA DECISIONP910023/S479

What did the FDA approve?

FDA records P910023/S479 as a supplement to PMA P910023, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Aug 27, 2025.

FDA approval order statement

expansion of MR Conditial labeling for IsoFlex model 1944 pacing leads and additional Quartet LV pacing leads (75cm and 92cm) when combined with Avant, Gallant, Entrant, and Neutrino NxT implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds).
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Aug 27, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P910023/S479
Regulatory pathway
PMA supplement
Product code
LWS
Decision code
APPR
Decision date
Aug 27, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P910023/S479 received

    Application receipt date recorded by FDA.

  2. P910023/S481 · Related supplement

    Avant VR (CDVRA700Q, CDVRA700T); Neutrino NxT VR (CDVRA800Q, CDVRA800T CDVRA600Q, CDVRA600T); Gallant VR (CDVRA500Q,

  3. P910023/S479 · FDA decision

    Real-Time Process

  4. P910023/S483 · Related supplement

    Avant (CDVRA700Q, CDVRA700T); Neutrino NxT (CDVRA800Q, CDVRA800T, CDVRA600Q, CDVRA600T); Gallant (CDVRA500Q, CDVRA500T);

  5. P910023/S485 · Related supplement

    Avant (CDVRA700Q, CDDRA700Q, CDVRA700T, CDDRA700T); Neutrino NxT (CDVRA800Q, CDVRA600Q CDDRA800Q, CDDRA600Q CDVRA600T, C

  6. P910023/S484 · Related supplement

    Current, Current Accel, Current+, Ellipse, Fortify, Fortify Assura, Epic/Epic+, Atlas/II/+ family of ICDs

  7. P910023/S486 · Related supplement

    Avant (CDVRA700Q, CDVRA700T); Neutrino NxT (CDVRA800Q, CDVRA800T, CDVRA600Q, CDVRA600T); Gallant (CDVRA500Q, CDVRA500T);

  8. P910023/S482 · Related supplement

    Current, Current Accel, Current+, Ellipse, Fortify, Fortify Assura, Epic/Epic+, Atlas/II/+ family of ICDs

  9. P910023/S487 · Related supplement

    Avant (CDVRA700Q, CDDRA700Q, CDVRA700T, CDDRA700T); Neutrino NxT (CDVRA800Q, CDVRA600Q, CDDRA800Q, CDDRA600Q, CDVRA600T,

Timeline entries are records held by MedtechLedger for P910023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P910023

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
15900 Valley View Ct., Sylmar, CA, 91335

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records